Total Valuation
Iovance Biotherapeutics has a market cap or net worth of €3.36B. The enterprise value is €1.62K.
Market Cap€3.36B
Enterprise Value€1.62K
Share Statistics
Iovance Biotherapeutics has 452,971,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding452,971,440
Owned by Insiders0.34%
Owned by Institutions14.92%
Financial Efficiency
Iovance Biotherapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -51.52%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.52%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee270.26K
Profits Per Employee-401.00K
Employee Count975
Asset Turnover0.29
Inventory Turnover0.14
Valuation Ratios
The current PE Ratio of Iovance Biotherapeutics is ―. Iovance Biotherapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio3.70
PB Ratio1.40
Price to Fair Value1.40
Price to FCF-2.90
Price to Operating Cash Flow-14.66
PEG Ratio0.17
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 263.50M and earned -390.98M in profits. Earnings per share was -1.09.
Revenue263.50M
Gross Profit256.22M
Operating Income-403.36M
Pretax Income-393.05M
Net Income-390.98M
EBITDA-357.11M
Earnings Per Share (EPS)-1.09
Cash Flow
In the last 12 months, operating cash flow was -264.18M and capital expenditures -32.21M, giving a free cash flow of -296.39M billion.
Operating Cash Flow-264.18M
Free Cash Flow-296.39M
Free Cash Flow per Share-0.65
Dividends & Yields
Iovance Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.46
52-Week Price Change255.77%
50-Day Moving Average5.43
200-Day Moving Average3.49
Relative Strength Index (RSI)55.48
Average Volume (3m)702.00
Important Dates
Iovance Biotherapeutics upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Iovance Biotherapeutics as a current ratio of 3.20, with Debt / Equity ratio of 6.25%
Current Ratio3.20
Quick Ratio2.83
Debt to Market Cap<0.01
Net Debt to EBITDA0.32
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Iovance Biotherapeutics has paid -2.07M in taxes.
Income Tax-2.07M
Effective Tax Rate<0.01
Enterprise Valuation
Iovance Biotherapeutics EV to EBITDA ratio is -2.41, with an EV/FCF ratio of -2.56.
EV to Sales3.27
EV to EBITDA-2.41
EV to Free Cash Flow-2.56
EV to Operating Cash Flow-2.85
Balance Sheet
Iovance Biotherapeutics has €297.67M in cash and marketable securities with €46.00M in debt, giving a net cash position of €251.67M billion.
Cash & Marketable Securities€297.67M
Total Debt€46.00M
Net Cash€251.67M
Net Cash Per Share€0.56
Tangible Book Value Per Share€1.17
Margins
Gross margin is 116.30%, with operating margin of -153.08%, and net profit margin of -148.38%.
Gross Margin116.30%
Operating Margin-153.08%
Pretax Margin-149.16%
Net Profit Margin-148.38%
EBITDA Margin-135.52%
EBIT Margin-149.16%
Analyst Forecast
The average price target for Iovance Biotherapeutics is €7.87, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€7.87
Price Target Upside7.85% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast25.45%
EPS Growth Forecast45.23%